drugset

drugset / Trial / NCT04354961

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

NCT04354961 ↗

Phase 2 Unknown 13 enrolled Fujian Cancer Hospital Jiangsu Hansoh Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multi-center, single-arm clinical trial.

Timeline

Start: 2021-05-07
Primary completion: 2023-12-31
Completion: 2025-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Almonertinib	Small molecule	110 mg	Oral

Indications